With experienced board and management and world-class scientific founders and advisors, Chikujee combines pioneering capability in the emerging field of Targeted Drug Delivery with extensive experience in the development of novel therapeutic agents.


Arkesh Mehta, PhD
Edmund “Morrie” Ruffin, MA
Ravi Kiron, PhD., MBA

Ravi Kiron, PhD
Dr. Kiron is Managing partner at Adjuvant Global Advisors. Prior to Adjuvant, Dr. Ravi Kiron was at LifeTech Innovations as Chief Operating Officer in 2007.  He has over 20 years of experience in the pharmaceutical and healthcare industries. Dr. Kiron is well versed in all aspects of drug discovery and delivery; pre-clinical and early clinical drug development; bioinformatics and database management; and M&A, investment due-diligence, and alliance management.
Prior to LifeTech, he was the Executive Director for New Technology Assessment and Planning at Johnson & Johnson / ALZA Corporation. His responsibilities included: drug delivery technology & research strategy and planning, in- and out-licensing, M&A and intellectual property management. Prior to Johnson & Johnson, Dr. Kiron spent 13 years in appointments of increasing responsibility at Pfizer Global R&D culminating with the position of Global Head, Strategic Analysis & KM, Strategic Alliances. While at Pfizer, he was a primary architect or key team member of many US and non-US based partnerships and deal transactions, and a member of the acquisition/integration team for Pfizer’s purchase of Warner-Lambert and Pharmacia Corporation, and performed due diligence on a number of biotech M&A opportunities. Dr. Kiron obtained experience in exploratory drug development as the project champion at Pfizer that led to the IND filing of Tarceva^®, now in widespread use for the treatment of multiple malignancies. He also led drug discovery research teams in cardiovascular and metabolic disorders, working on hypertension, congestive heart failure and ischemia-reperfusion injuries.
Prior to Pfizer, Dr. Kiron was a biochemistry and medicine faculty member at Cornell University Medical Center in New York. He holds a BSc in Chemistry and an MSc in Microbiology from Bombay University, India. He also has a PhD in Biochemistry from the Indian Institute of Science in Bangalore, India and an MBA from Rensselaer in Hartford, Connecticut.